Trending...
- Trump's Executive Order Rescheduling Cannabis: Accelerating M&A in a Multibillion-Dollar Industry
- Chicago: Mayor Brandon Johnson Signs "Fair Recovery" Executive Order, Prohibiting Sale of Medical Debt, Establishing Responsible Debt Collection Standards
- HBZBZL Unveils "Intelligent Ecosystem" Strategy: Integrating AI Analytics with Web3 Incubation
SEOUL, South Korea, June 10, 2024 ~ During the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, J INTS BIO provided an update on their Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for the treatment of non-small cell lung cancer (NSCLC). The update was presented during the poster session on June 3rd.
The study, which began in May 2024 and is ongoing, aims to evaluate the safety and efficacy of JIN-A02 in patients with NSCLC. Professor Cho Byoung Chul, a leading researcher in the field of oncology, presented the update and posed with the JIN-A02 poster at the conference.
The latest update reported a partial response (PR) in a patient from Cohort 4 who received a daily dose of 100mg. This is the second PR recorded in the study, with the first being from a patient in an earlier cohort who received a lower dose of 50mg daily. Additionally, this is also the first instance of brain tumor activity being observed in Cohort 4, with a reduction of brain metastasis by 28.6%.
More on illi News
So far, two patients have shown partial response and three others have stable disease. This includes the patient from Cohort 4 with reduced brain metastasis and two patients from lower cohorts who received lower doses.
The final patient in Cohort 4 is expected to complete their dose-limiting toxicity (DLT) assessment soon and no DLT has been detected thus far. Furthermore, there have been no reports of common side effects such as rash, diarrhea or cardiac toxicity associated with EGFR TKIs use.
J INTS BIO expressed their excitement about sharing these key clinical results at such a prestigious conference attended by global anticancer experts and research and development officials. They also stated that JIN-A02 has potential to be a game changer in improving the lives of patients with EGFR C797S positive NSCLC, for which there is currently no approved treatment. The company plans to enter phase 2 clinical trials by the end of this year.
The next cohort, which will receive a daily dose of 150mg, is set to begin at the end of June. J INTS BIO believes that these results will pave the way for further advancements in the treatment of NSCLC and bring hope to patients and their families.
The study, which began in May 2024 and is ongoing, aims to evaluate the safety and efficacy of JIN-A02 in patients with NSCLC. Professor Cho Byoung Chul, a leading researcher in the field of oncology, presented the update and posed with the JIN-A02 poster at the conference.
The latest update reported a partial response (PR) in a patient from Cohort 4 who received a daily dose of 100mg. This is the second PR recorded in the study, with the first being from a patient in an earlier cohort who received a lower dose of 50mg daily. Additionally, this is also the first instance of brain tumor activity being observed in Cohort 4, with a reduction of brain metastasis by 28.6%.
More on illi News
- The 22% Tax Reality: Finland's New Gambling Law Creates a "Fiscal Trap" for Grey Market Casino Players
- Inkdnylon Launches Ask Inkdnylon Decision Platform
- Phinge Founder & CEO Robert DeMaio Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes
- A Chicago Woman Dies In A Shooting-related Car Crash
- Donna Cardellino Manager/Facilitator Signs Justin Jeansonne Country Singer-Songwriter To Exclusive Management Deal For Global Music Expansion
So far, two patients have shown partial response and three others have stable disease. This includes the patient from Cohort 4 with reduced brain metastasis and two patients from lower cohorts who received lower doses.
The final patient in Cohort 4 is expected to complete their dose-limiting toxicity (DLT) assessment soon and no DLT has been detected thus far. Furthermore, there have been no reports of common side effects such as rash, diarrhea or cardiac toxicity associated with EGFR TKIs use.
J INTS BIO expressed their excitement about sharing these key clinical results at such a prestigious conference attended by global anticancer experts and research and development officials. They also stated that JIN-A02 has potential to be a game changer in improving the lives of patients with EGFR C797S positive NSCLC, for which there is currently no approved treatment. The company plans to enter phase 2 clinical trials by the end of this year.
The next cohort, which will receive a daily dose of 150mg, is set to begin at the end of June. J INTS BIO believes that these results will pave the way for further advancements in the treatment of NSCLC and bring hope to patients and their families.
Filed Under: Business
0 Comments
Latest on illi News
- Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow
- A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations
- Chicago: Mayor Brandon Johnson Signs Executive Order Capping Police Overtime Spending, Creates New Oversight Framework
- Chicago: Mayor Brandon Johnson Signs "Fair Recovery" Executive Order, Prohibiting Sale of Medical Debt, Establishing Responsible Debt Collection Standards
- Guests Can Save 25 Percent Off Last Minute Bookings at KeysCaribbean's Village at Hawks Cay Villas
- Trump's Executive Order Rescheduling Cannabis: Accelerating M&A in a Multibillion-Dollar Industry
- Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Birmingham SE / Liberty Park
- Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
- Price Improvement on Luxurious Lāna'i Townhome with Stunning Ocean Views
- Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026
- Digi 995 Expands Its Puzzle Lineup With the Release of Digi 995: Word Maze on Mobile Platforms
- CredHub and Real Property Management Join Forces to Empower Franchise Owners with Rental Payment Credit Reporting Solutions
- Leimert Park Announces Weeklong Kwanzaa Festival & Kwanzaa Parade Celebrating Black History, Culture, and Community
- Renowned Alternative Medicine Specialist Dr. Sebi and His African Bio Mineral Balance Therapy Are the Focus of New Book
- Psychiatric Drug Damage Ignored for Decades; CCHR Demands Federal Action
- Phil Marley Releases Two Music Projects While Seeking Kidney Donor
- Why Millions Are Losing Sexual Sensation, And Why It's Not Age, Hormones, or Desire
- Justin Jeansonne An Emerging Country Singer-Songwriter Music Fans Have Been Waiting For…a True Maverick
- Russellville Huntington Learning Center Expands Access to Literacy Support; Approved Provider Under Arkansas Department of Education
- UK Financial Ltd Launches U.S. Operations Following Delaware Approval